Copyright
©2010 Baishideng.
World J Gastrointest Oncol. May 15, 2010; 2(5): 213-217
Published online May 15, 2010. doi: 10.4251/wjgo.v2.i5.213
Published online May 15, 2010. doi: 10.4251/wjgo.v2.i5.213
Study | n | Therapy | Timing | Response criteria | Outcome measure | Result | P |
Engenhart et al[7] (1992) | 21 | RT | 8-9 wk pc | ΔSUV | LC | SUV normalization; PPV 20%; NPV 67% | |
Schiepers et al[14] (1999) | 9 | RT | 2-3 wk pc | TuGluc | Histo, cell kinetics | Decreased 138 nmol/mL per min after RT | 0.008 |
Guillem et al[11] (2000) | 15 | CRT | 4-5 wk pc | ΔSUV, VR, δTLG | Histo | VR PPV 60% | |
Oku et al[9] (2002) | 40 | RT | 3-5 wk pc | SUV | Recurrence | SUV < 3.2 | < 0.05 |
Amthauer et al[15] (2004) | 20 | CRT + H | 2-4 wk pc | ΔSUV | Histo | 36% decrease SUV PPV 93%; NPV 100% | 0.003 |
Calvo et al[16] (2004) | 25 | CRT | 4-5 wk pc | ΔSUV | Histo | 2 vs 2.7 decrease SUV | NS |
Guillem et al[17] (2004) | 15 | CRT | 4-5 wk pc | ΔSUV, VR, δTLG | Recurrence, OS, RFS | 63% decrease SUV 70% decrease TLG | 0.08 0.03 |
Denecke et al[18] (2005) | 23 | CRT + H | 2-4 wk pc | ΔSUV | Histo | 36% decrease SUV PPV 77%; NPV 100% | 0.002 |
Konski et al[19] (2005) | 20 | CRT | 3-4 wk pc | ΔSUV | Histo | 52% vs 75% decrease SUV | NS |
Cascini et al[20] (2006) | 33 | CRT | 12 d pi | ΔSUV | Histo | 22% vs 63% decrease SUV | < 0.0001 |
Capirci et al[13] (2006) | 88 | CRT | 5-6 wk pc | Negative PET | 5 yr OS and DFS | 91% vs 72% 81% vs 62% | 0.024 0.003 |
Kalff et al[12] (2006) | 34 | CRT | 7-43 d pc | VR | OS PFS | 100% vs 79% 100% vs 47% | < 0.0001 < 0.0001 |
Capirci et al[21] (2007) | 45 | CRT | 5-6 wk pc | ΔSUV | Histo | 66% decrease SUV PPV 77%; NPV 89% | 0.0015 |
Melton et al[22] (2007) | 21 | CRT | 4-5 wk pc | ΔSUV, VR, δTLG | Histo | 70% decrease SUV PPV 58%; NPV 100% | < 0.001 |
Kristiansen et al[23] (2008) | 30 | CRT | 7 wk pc | VR | Histo | PPV 83%; NPV 33% | NS |
Siegel et al[8] (2008) | 32 | RT (short) | 7-8 d pi | ΔSUV | Histo | 40% decrease SUV | NS |
Nakagawa et al[10] (2008) | 59 | RT | 2-3 wk pc | SUV | OS MS | SUV < 5: 95 vs 42 mo, 70% vs 44% | 0.042 |
Vliegen et al[24] (2008) | 20 | CRT | 4-6 wk pc | ΔSUV | Histo | 83% vs 59% decrease SUV | 0.025 |
Janssen et al[25] (2009) | 30 | CRT | 2 wk pc | ΔSUV | Histo | 43% decrease SUV PPV 91%; NPV 82% | |
Konski et al[26] (2009) | 53 | CRT | 3-4 wk pc | ΔSUV | Histo | 67% vs 55% decrease SUV | NS |
Rosenberg et al[27] (2009) | 30 | CRT | pc | ΔSUV | Histo | 66% vs 48% decrease SUV PPV 83%; NPV 64% | 0.040 |
- Citation: Hopkins S, Fakih M, Yang GY. Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. World J Gastrointest Oncol 2010; 2(5): 213-217
- URL: https://www.wjgnet.com/1948-5204/full/v2/i5/213.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v2.i5.213